Lindor
NM, McMaster ML, Lindor CJ, Greene MH; National Cancer Institute,
Division of Cancer Prevention, Community Oncology and Prevention Trials
Research Group. Concise handbook of familial cancer
susceptibility syndromes - second edition. J Natl Cancer Inst Monogr.
2008:1-93. [PMID: 18559331]
Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, et al, eds. SEER Cancer Statistics Review, 1975–2010. Bethesda, MD: National Cancer Institute; 2013. Accessed at
http://seer.cancer.gov/csr/1975_2010 on 14 November 2013.
Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al.
Average risks of breast and ovarian cancer associated with BRCA1 or
BRCA2 mutations detected in case series unselected for family history: a
combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117-30.
[PMID: 12677558]
Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25:1329-33. [PMID: 17416853]
Prevalence
and penetrance of BRCA1 and BRCA2 mutations in a population-based
series of breast cancer cases. Anglian Breast Cancer Study Group. Br J
Cancer. 2000;83:1301-8. [PMID: 11044354]
Antoniou AC, Gayther SA, Stratton JF, Ponder BA, Easton DF. Risk models for familial ovarian and breast cancer. Genet Epidemiol. 2000;18:173-90. [PMID: 10642429]
Antoniou AC, Pharoah PD, McMullan G, Day NE, Stratton MR, Peto J, et al.
A comprehensive model for familial breast cancer incorporating BRCA1,
BRCA2 and other genes. Br J Cancer. 2002;86:76-83. [PMID: 11857015]
Peto J, Collins N, Barfoot R, Seal S, Warren W, Rahman N, et al.
Prevalence of BRCA1 and BRCA2 gene mutations in patients with
early-onset breast cancer. J Natl Cancer Inst. 1999;91:943-9. [PMID:
10359546]
Nelson HD, Fu R, Goddard K, Priest Mitchell J, Okinaka-Hu L, Pappas M, et al.
Risk Assessment, Genetic Counseling, and Genetic Testing for
BRCA-Related Cancer: Systematic Review to Update the U.S. Preventive
Services Task Force Recommendation. Evidence synthesis no. 101. AHRQ
publication no. 12-05164-EF-1. Rockville, MD: Agency for Healthcare
Research and Quality; 2013.
Panchal SM, Ennis M, Canon S, Bordeleau LJ. Selecting a BRCA risk assessment model for use in a familial cancer clinic. BMC Med Genet. 2008;9:116. [PMID: 19102775]
Parmigiani G, Chen S, Iversen ES Jr, Friebel TM, Finkelstein DM, Anton-Culver H, et al. Validity of models for predicting BRCA1 and BRCA2 mutations. Ann Intern Med. 2007;147:441-50. [PMID: 17909205]
Oros KK, Ghadirian P, Maugard CM, Perret C, Paredes Y, Mes-Masson AM, et al.
Application of BRCA1 and BRCA2 mutation carrier prediction models in
breast and/or ovarian cancer families of French Canadian descent. Clin
Genet. 2006;70:320-9. [PMID: 16965326]
Evans DG, Eccles DM, Rahman N, Young K, Bulman M, Amir E, et al.
A new scoring system for the chances of identifying a BRCA1/2 mutation
outperforms existing models including BRCAPRO. J Med Genet.
2004;41:474-80. [PMID: 15173236]
Barcenas CH, Hosain GM, Arun B, Zong J, Zhou X, Chen J, et al. Assessing BRCA carrier probabilities in extended families. J Clin Oncol. 2006;24:354-60. [PMID: 16421416]
Antoniou AC, Hardy R, Walker L, Evans DG, Shenton A, Eeles R, et al.
Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation:
validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring
system using data from UK genetics clinics. J Med Genet.
2008;45:425-31. [PMID: 18413374]
Bellcross CA, Lemke AA, Pape LS, Tess AL, Meisner LT.
Evaluation of a breast/ovarian cancer genetics referral screening tool
in a mammography population. Genet Med. 2009;11:783-9. [PMID: 19752737]
Hoskins KF, Zwaagstra A, Ranz M.
Validation of a tool for identifying women at high risk for hereditary
breast cancer in population-based screening. Cancer. 2006;107:1769-76.
[PMID: 16967460]
Ashton-Prolla P, Giacomazzi J, Schmidt AV, Roth FL, Palmero EI, Kalakun L, et al.
Development and validation of a simple questionnaire for the
identification of hereditary breast cancer in primary care. BMC Cancer.
2009;9:283. [PMID: 19682358]
Gilpin CA, Carson N, Hunter AG.
A preliminary validation of a family history assessment form to select
women at risk for breast or ovarian cancer for referral to a genetics
center. Clin Genet. 2000;58:299-308. [PMID: 11076055]
Nelson H, Pappas M, Zakher B, Mitchell J, Okinaka-Hu L, Fu R.
Risk assessment, genetic counseling, and genetic testing for
BRCA-related cancer in women: a systematic review to update the U.S.
Preventive Services Task Force recommendation. Ann Intern Med. 2013.
Gronwald J, Cybulski C, Lubinski J, Narod SA.
Phenocopies in breast cancer 1 (BRCA1) families: implications for
genetic counselling [Letter]. J Med Genet. 2007;44:e76. [PMID: 17400795]
Rowan E, Poll A, Narod SA.
A prospective study of breast cancer risk in relatives of BRCA1/BRCA2
mutation carriers. J Med Genet. 2007;44:e89. [PMID: 17673443]
Smith A, Moran A, Boyd MC, Bulman M, Shenton A, Smith L, et al.
Phenocopies in BRCA1 and BRCA2 families: evidence for modifier genes
and implications for screening. J Med Genet. 2007;44:10-15. [PMID:
17079251]
Vos JR, de Bock GH, Teixeira N, van der Kolk DM, Jansen L, Mourits MJ, et al. Proven non-carriers in BRCA families have an earlier age of onset of breast cancer. Eur J Cancer. 2013. [PMID: 23490645]
Finch A, Metcalfe KA, Chiang J, Elit L, McLaughlin J, Springate C, et al.
The impact of prophylactic salpingo-oophorectomy on quality of life and
psychological distress in women with a BRCA mutation. Psychooncology.
2013;22:212-9. [PMID: 21913283]
Nelson HD, Smith ME, Griffin JC, Fu R.
Use of medications to reduce risk for primary breast cancer: a
systematic review for the U.S. Preventive Services Task Force. Ann
Intern Med. 2013;158:604-14. [PMID: 23588749]
Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, et al.
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation
carriers with cancer risk and mortality. JAMA. 2010;304:967-75. [PMID:
20810374]
Skytte AB, Crüger D, Gerster M, Laenkholm AV, Lang C, Brøndum-Nielsen K, et al. Breast cancer after bilateral risk-reducing mastectomy. Clin Genet. 2011;79:431-7. [PMID: 21199491]
Evans DG, Gaarenstroom KN, Stirling D, Shenton A, Maehle L, Dørum A, et al. Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers. J Med Genet. 2009;46:593-7. [PMID: 18413372]
Centers for Disease Control and Prevention. Breast Cancer Statistics. Atlanta, GA: Centers for Disease Control and Prevention; 2013. Accessed at
www.cdc.gov/cancer/breast/statistics on 14 November 2013.
Centers for Disease Control and Prevention, National Cancer Institute, North American Association of Central Cancer Registries.
United States Cancer Statistics: 1999–2010 Cancer Incidence and
Mortality Data. Atlanta, GA: Centers for Disease Control and Prevention;
2013. Accessed at
http://apps.nccd.cdc.gov/uscs on 9 December 2013.
FitzGerald MG, MacDonald DJ, Krainer M, Hoover I, O'Neil E, Unsal H, et al.
Germ-line BRCA1 mutations in Jewish and non-Jewish women with
early-onset breast cancer. N Engl J Med. 1996;334:143-9. [PMID: 8531968]
Malone KE, Daling JR, Neal C, Suter NM, O'Brien C, Cushing-Haugen K, et al.
Frequency of BRCA1/BRCA2 mutations in a population-based sample of
young breast carcinoma cases. Cancer. 2000;88:1393-402. [PMID: 10717622]
Fodor FH, Weston A, Bleiweiss IJ, McCurdy LD, Walsh MM, Tartter PI, et al.
Frequency and carrier risk associated with common BRCA1 and BRCA2
mutations in Ashkenazi Jewish breast cancer patients. Am J Hum Genet.
1998;63:45-51. [PMID: 9634504]
Hartge P, Struewing JP, Wacholder S, Brody LC, Tucker MA. The prevalence of common BRCA1 and BRCA2 mutations among Ashkenazi Jews. Am J Hum Genet. 1999;64:963-70. [PMID: 10090881]
Metcalfe KA, Poll A, Royer R, Llacuachaqui M, Tulman A, Sun P, et al. Screening for founder mutations in BRCA1 and BRCA2 in unselected Jewish women. J Clin Oncol. 2010;28:387-91. [PMID: 20008623]
Roa BB, Boyd AA, Volcik K, Richards CS. Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nat Genet. 1996;14:185-7. [PMID: 8841191]
Armstrong K, Micco E, Carney A, Stopfer J, Putt M.
Racial differences in the use of BRCA1/2 testing among women with a
family history of breast or ovarian cancer. JAMA. 2005;293:1729-36.
[PMID: 15827311]
Roshanai AH, Rosenquist R, Lampic C, Nordin K.
Does enhanced information at cancer genetic counseling improve
counselees' knowledge, risk perception, satisfaction and negotiation of
information to at-risk relatives?—a randomized study. Acta Oncol.
2009;48:999-1009. [PMID: 19636983]
Matloff ET, Moyer A, Shannon KM, Niendorf KB, Col NF.
Healthy women with a family history of breast cancer: impact of a
tailored genetic counseling intervention on risk perception, knowledge,
and menopausal therapy decision making. J Womens Health (Larchmt).
2006;15:843-56. [PMID: 16999640]
Bloom JR, Stewart SL, Chang S, You M.
Effects of a telephone counseling intervention on sisters of young
women with breast cancer. Prev Med. 2006;43:379-84. [PMID: 16916540]
Braithwaite D, Sutton S, Mackay J, Stein J, Emery J.
Development of a risk assessment tool for women with a family history
of breast cancer. Cancer Detect Prev. 2005;29:433-9. [PMID: 16055276]
Helmes AW, Culver JO, Bowen DJ.
Results of a randomized study of telephone versus in-person breast
cancer risk counseling. Patient Educ Couns. 2006;64:96-103. [PMID:
16427245]
Bowen DJ, Burke W, Culver JO, Press N, Crystal S.
Effects of counseling Ashkenazi Jewish women about breast cancer risk.
Cultur Divers Ethnic Minor Psychol. 2006;12:45-56. [PMID: 16594854]
Mikkelsen EM, Sunde L, Johansen C, Johnsen SP.
Risk perception among women receiving genetic counseling: a
population-based follow-up study. Cancer Detect Prev. 2007;31:457-64.
[PMID: 18061369]
Mikkelsen EM, Sunde L, Johansen C, Johnsen SP. Psychosocial consequences of genetic counseling: a population-based follow-up study. Breast J. 2009;15:61-8. [PMID: 19120380]
Pieterse AH, Ausems MG, Spreeuwenberg P, van Dulmen S.
Longer-term influence of breast cancer genetic counseling on cognitions
and distress: smaller benefits for affected versus unaffected women.
Patient Educ Couns. 2011;85:425-31. [PMID: 21316181]
Hopwood P, Wonderling D, Watson M, Cull A, Douglas F, Cole T, et al.
A randomised comparison of UK genetic risk counselling services for
familial cancer: psychosocial outcomes. Br J Cancer. 2004;91:884-92.
[PMID: 15305197]
Kelly KM, Senter L, Leventhal H, Ozakinci G, Porter K.
Subjective and objective risk of ovarian cancer in Ashkenazi Jewish
women testing for BRCA1/2 mutations. Patient Educ Couns. 2008;70:135-42.
[PMID: 17988821]
Gurmankin AD, Domchek S, Stopfer J, Fels C, Armstrong K. Patients' resistance to risk information in genetic counseling for BRCA1/2. Arch Intern Med. 2005;165:523-9. [PMID: 15767527]
Bennett P, Wilkinson C, Turner J, Brain K, Edwards RT, Griffith G, et al.
Psychological factors associated with emotional responses to receiving
genetic risk information. J Genet Couns. 2008;17:234-41. [PMID:
18259848]
Brain K, Parsons E, Bennett P, Cannings-John R, Hood K.
The evolution of worry after breast cancer risk assessment: 6-year
follow-up of the TRACE study cohort. Psychooncology. 2011;20:984-91.
[PMID: 20677331]
Fry A, Cull A, Appleton S, Rush R, Holloway S, Gorman D, et al.
A randomised controlled trial of breast cancer genetics services in
South East Scotland: psychological impact. Br J Cancer. 2003;89:653-9.
[PMID: 12915873]
Smerecnik CM, Mesters I, Verweij E, de Vries NK, de Vries H.
A systematic review of the impact of genetic counseling on risk
perception accuracy. J Genet Couns. 2009;18:217-28. [PMID: 19291376]
Bennett P, Wilkinson C, Turner J, Edwards RT, France B, Griffith G, et al.
Factors associated with intrusive cancer-related worries in women
undergoing cancer genetic risk assessment. Fam Cancer. 2009;8:159-65.
[PMID: 19011994]
Fisher B, Costantino JP, Wickerham DL, Cecchini RS, Cronin WM, Robidoux A, et al.
Tamoxifen for the prevention of breast cancer: current status of the
National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl
Cancer Inst. 2005;97:1652-62. [PMID: 16288118]
Powles TJ, Ashley S, Tidy A, Smith IE, Dowsett M.
Twenty-year follow-up of the Royal Marsden randomized, double-blinded
tamoxifen breast cancer prevention trial. J Natl Cancer Inst.
2007;99:283-90. [PMID: 17312305]
Veronesi U, Maisonneuve P, Rotmensz N, Bonanni B, Boyle P, Viale G, et al; Italian Tamoxifen Study Group.
Tamoxifen for the prevention of breast cancer: late results of the
Italian Randomized Tamoxifen Prevention Trial among women with
hysterectomy. J Natl Cancer Inst. 2007;99:727-37. [PMID: 17470740]
Cuzick
J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli K, et al;
International Breast Cancer Intervention Study I Investigators.
Long-term results of tamoxifen prophylaxis for breast cancer—96-month
follow-up of the randomized IBIS-I trial. J Natl Cancer Inst.
2007;99:272-82. [PMID: 17312304]
Grady D, Cauley JA, Geiger MJ, Kornitzer M, Mosca L, Collins P, et al; Raloxifene Use for The Heart Trial Investigators.
Reduced incidence of invasive breast cancer with raloxifene among women
at increased coronary risk. J Natl Cancer Inst. 2008;100:854-61. [PMID:
18544744]
Lippman ME, Cummings SR, Disch DP, Mershon JL, Dowsett SA, Cauley JA, et al.
Effect of raloxifene on the incidence of invasive breast cancer in
postmenopausal women with osteoporosis categorized by breast cancer
risk. Clin Cancer Res. 2006;12:5242-7. [PMID: 16951244]
Vogel
VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et
al; National Surgical Adjuvant Breast and Bowel Project.
Update of the National Surgical Adjuvant Breast and Bowel Project Study
of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer.
Cancer Prev Res (Phila). 2010;3:696-706. [PMID: 20404000]
Nelson HD, Fu R, Humphrey L, Smith M, Griffin JC, Nygren P.
Comparative Effectiveness of Medications to Reduce Risk of Primary
Breast Cancer in Women. Comparative effectiveness review no. 17.
Rockville, MD: Agency for Healthcare Research and Quality; 2009.
Kurian AW, Gong GD, John EM, Johnston DA, Felberg A, West DW, et al.
Breast cancer risk for noncarriers of family-specific BRCA1 and BRCA2
mutations: findings from the Breast Cancer Family Registry. J Clin
Oncol. 2011;29:4505-9. [PMID: 22042950]
Eisen A, Lubinski J, Klijn J, Moller P, Lynch HT, Offit K, et al.
Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2
mutation carriers: an international case-control study. J Clin Oncol.
2005;23:7491-6. [PMID: 16234515]
Kriege M, Brekelmans CT, Boetes C, Muller SH, Zonderland HM, Obdeijn IM, et al; Dutch MRI Screening (MRISC) Study Group.
Differences between first and subsequent rounds of the MRISC breast
cancer screening program for women with a familial or genetic
predisposition. Cancer. 2006;106:2318-26. [PMID: 16615112]
Le-Petross HT, Whitman GJ, Atchley DP, Yuan Y, Gutierrez-Barrera A, Hortobagyi GN, et al.
Effectiveness of alternating mammography and magnetic resonance imaging
for screening women with deleterious BRCA mutations at high risk of
breast cancer. Cancer. 2011;117:3900-7. [PMID: 21365619]
Contant CM, Menke-Pluijmers MB, Seynaeve C, Meijers-Heijboer EJ, Klijn JG, Verhoog LC, et al.
Clinical experience of prophylactic mastectomy followed by immediate
breast reconstruction in women at hereditary risk of breast cancer
(HB(O)C) or a proven BRCA1 and BRCA2 germ-line mutation. Eur J Surg
Oncol. 2002;28:627-32. [PMID: 12359199]
Metcalfe KA, Esplen MJ, Goel V, Narod SA.
Psychosocial functioning in women who have undergone bilateral
prophylactic mastectomy. Psychooncology. 2004;13:14-25. [PMID: 14745742]
Kauff ND, Satagopan JM, Robson ME, Scheuer L, Hensley M, Hudis CA, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002;346:1609-15. [PMID: 12023992]
Brandberg Y, Arver B, Johansson H, Wickman M, Sandelin K, Liljegren A.
Less correspondence between expectations before and cosmetic results
after risk-reducing mastectomy in women who are mutation carriers: a
prospective study. Eur J Surg Oncol. 2012;38:38-43. [PMID: 22032910]
Brandberg Y, Sandelin K, Erikson S, Jurell G, Liljegren A, Lindblom A, et al.
Psychological reactions, quality of life, and body image after
bilateral prophylactic mastectomy in women at high risk for breast
cancer: a prospective 1-year follow-up study. J Clin Oncol.
2008;26:3943-9. [PMID: 18711183]
Gahm J, Wickman M, Brandberg Y.
Bilateral prophylactic mastectomy in women with inherited risk of
breast cancer—prevalence of pain and discomfort, impact on sexuality,
quality of life and feelings of regret two years after surgery. Breast.
2010;19:462-9. [PMID: 20605453]
Wasteson E, Sandelin K, Brandberg Y, Wickman M, Arver B.
High satisfaction rate ten years after bilateral prophylactic
mastectomy - a longitudinal study. Eur J Cancer Care (Engl).
2011;20:508-13. [PMID: 20597955]
Finch A, Metcalfe KA, Chiang JK, Elit L, McLaughlin J, Springate C, et al.
The impact of prophylactic salpingo-oophorectomy on menopausal symptoms
and sexual function in women who carry a BRCA mutation. Gynecol Oncol.
2011;121:163-8. [PMID: 21216453]
Nelson HD, Huffman LH, Fu R, Harris EL; U.S. Preventive Services Task Force.
Genetic risk assessment and BRCA mutation testing for breast and
ovarian cancer susceptibility: systematic evidence review for the U.S.
Preventive Services Task Force. Ann Intern Med. 2005;143:362-79. [PMID:
16144895]
American College of Obstetricians and Gynecologists.
ACOG Practice Bulletin No. 103: Hereditary breast and ovarian cancer
syndrome. Obstet Gynecol. 2009;113:957-66. [PMID: 19305347]
Robson ME, Storm CD, Weitzel J, Wollins DS, Offit K; American Society of Clinical Oncology.
American Society of Clinical Oncology policy statement update: genetic
and genomic testing for cancer susceptibility. J Clin Oncol.
2010;28:893-901. [PMID: 20065170]
Berliner JL, Fay AM, Cummings SA, Burnett B, Tillmanns T.
NSGC practice guideline: risk assessment and genetic counseling for
hereditary breast and ovarian cancer. J Genet Couns. 2013;22:155-63.
[PMID: 23188549]
Balmaña J, Díez O, Rubio IT, Cardoso F; ESMO Guidelines Working Group. BRCA in breast cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2011;22 Suppl 6:vi31-4. [PMID: 21908500]
Lancaster JM, Powell CB, Kauff ND, Cass I, Chen LM, Lu KH, et al; Society of Gynecologic Oncologists Education Committee.
Society of Gynecologic Oncologists Education Committee statement on
risk assessment for inherited gynecologic cancer predispositions.
Gynecol Oncol. 2007;107:159-62. [PMID: 17950381]
